XWELL (NASDAQ:XWEL) & iSpecimen (NASDAQ:ISPC) Head-To-Head Contrast

XWELL (NASDAQ:XWEL) and iSpecimen (NASDAQ:ISPC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and recommmendations for XWELL and iSpecimen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XWELL	1	0	0	0	1.00
iSpecimen	1	0	0	0	1.00

Earnings and Valuation

This table compares XWELL and iSpecimen”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XWELL	$33.90 million	0.21	-$16.85 million	($3.37)	-0.37
iSpecimen	$9.29 million	0.21	-$12.50 million	($7.89)	-0.03

iSpecimen has lower revenue, but higher earnings than XWELL. XWELL is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

XWELL has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, iSpecimen has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500.

Profitability

This table compares XWELL and iSpecimen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XWELL	-51.85%	-352.37%	-64.88%
iSpecimen	-343.86%	-531.78%	-147.74%

Insider & Institutional Ownership

8.7% of XWELL shares are held by institutional investors. Comparatively, 13.6% of iSpecimen shares are held by institutional investors. 13.9% of XWELL shares are held by company insiders. Comparatively, 12.2% of iSpecimen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

XWELL beats iSpecimen on 6 of the 11 factors compared between the two stocks.

About XWELL

XWELL, Inc. provides health and wellness services in airport and off airport marketplaces in the United States and internationally. It operates in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The XpresSpa segment traveler's spa services, including massage, nail, and skin care services, as well as spa and travel products. The XpresTest segment offers diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public but has transitioned to the CDC's bio-surveillance program; and provides marketing support through HyperPointe business to various health and health-related channels. The Napple Wax Center segment offers skincare and cometic products, as well as face and body waxing services. The Treat segment provides access to wellness services for travelers at on-site centers, consisting of self-guided yoga, meditation, and low impact weight exercises programs. The company offers its services through stores, kiosks, and online. The company was formerly known as XpresSpa Group, Inc. and changed its name to XWELL, Inc. in October 2022. XWELL, Inc. is based in New York, New York.

About iSpecimen

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.